Ann Lab Med.  2013 Mar;33(2):121-124. 10.3343/alm.2013.33.2.121.

Comparison of 3 Automated Immunoassays for Detection of Anti-Hepatitis A Virus Immunoglobulin M in a Tertiary Care Hospital

• Park H
• Lee YJ
• Seong MW
• Lee DH
• Park MH
• Song EY

• KMID: 1781311
• DOI: http://doi.org/10.3343/alm.2013.33.2.121

Abstract

Three automated immunoassay kits for anti-Hepatitis A Virus (HAV) IgM-Architect, (Abbott Laboratories, USA), Elecsys (Roche Diagnostics, Germany), and ADVIA Centaur (Siemens Healthcare Diagnostics Inc., USA)-were compared. We included 178 consecutive samples, for which an anti-HAV IgM test was requested at Seoul National University Hospital from September 2009 to January 2010. Reviewing of medical records, reverse transcription (RT)-PCR for HAV RNA, or total anti-HAV assay were performed on 16 (9.0%) samples with discrepant results. The percent agreements (kappas) of the Architect and ADVIA Centaur, Architect and Elecsys, and ADVIA Centaur and Elecsys kits were 96.6% (0.91), 96.6% (0.92), and 97.8% (0.94), respectively. Eight out of 16 discrepant samples showed gray-zone values in Architect but were nonreactive in the others. Slightly earlier seroconversion was suspected in Elecsys. The 3 assays showed comparable performances with excellent agreements in a tertiary care hospital setting.

Keyword

Anti-hepatitis A virus immunoglobulin M; Immunoassay; Agreement

MeSH Terms

Hepatitis A virus/genetics/*immunology
Hepatitis B/*diagnosis
Hospitals, University
Humans
Immunoassay/*methods
Immunoglobulin M/*analysis
RNA, Viral/analysis
Reagent Kits, Diagnostic
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Tertiary Healthcare
Immunoglobulin M
RNA, Viral
Reagent Kits, Diagnostic

Figure

• 

  Fig. 1 Correlations of signal-to-cutoff (S/CO) values among Architect HAVAb-IgM, ADVIA Centaur HAV IgM, and Elecsys Anti-HAV IgM assays. (A) Scatter plot of S/CO values of Architect HAVAb-IgM and ADVIA Centaur HAV IgM assays, (B) Architect HAVAb-IgM and Elecsys Anti-HAV IgM assays, and (C) ADVIA Centaur HAV IgM and Elecsys Anti-HAV IgM assays.Abbreviation: HAV, hepatitis A virus.

Reference

1. Dufour DR, Talastas M, Fernandez MD, Hwang JH, Kim JW, Kim NY, et al. Chemiluminescence assay improves specificity of hepatitis C antibody detection. Clin Chem. 2003; 49:940–944. PMID: 12765991.

2. Hess G, Faatz E, Melchior W, Bayer H. Analysis of immunoassays to detect antibodies to hepatitis A virus (anti-HAV) and anti-HAV immunoglobulin M. J Virol Methods. 1995; 51:221–228. PMID: 7738142.

3. Wiedmann M, Boehm S, Schumacher W, Swysen C, Zauke M. Evaluation of three commercial assays for the detection of hepatitis a virus. Eur J Clin Microbiol Infect Dis. 2003; 22:129–130. PMID: 12627291.

4. Clinical and Laboratory Standards Institute. Assessment of laboratory tests when proficiency testing is not available; Approved guideline. CLSI document, GP29-A. 2008. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute.

5. Mylonakis E, Paliou M, Lally M, Flanigan TP, Rich JD. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med. 2000; 109:568–576. PMID: 11063959.

6. Cavalier E, Carlisi A, Chapelle JP, Delanaye P. False positive PTH results: an easy strategy to test and detect analytical interferences in routine practice. Clin Chim Acta. 2008; 387:150–152. PMID: 17904113.

7. Kellar KL, Kalwar RR, Dubois KA, Crouse D, Chafin WD, Kane BE. Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants. Cytometry. 2001; 45:27–36. PMID: 11598944.

8. Berth M, Bosmans E. Prevention of assay interference in infectious-disease serology tests done on the liaison platform. Clin Vaccine Immunol. 2008; 15:891–892. PMID: 18337378.

9. Eisenbach C, Longerich T, Fickenscher H, Schalasta G, Stremmel W, Encke J. Recurrence of clinically significant hepatitis A following liver transplantation for fulminant hepatitis A. J Clin Virol. 2006; 35:109–112. PMID: 16185915.